myosin heavy chain 4Genealiases: MYH2B · MyHC-2B · MyHC-IIb
Q-omics provides the consensus-scored MYH4 profile across patient tissues and cancer cell-line models. MYH4 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MYH4 is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, MYH4 RNA expression shows 11,795 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight ACC, BLCA, and BRCA as cancer lineages where MYH4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYH4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYH4 survival associations across molecular data types. MYH4 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (12) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYH4 RNA expression–survival associations across cancer types. High MYH4 expression shows unfavorable associations in ACC, STAD, KICH, OV and THCA, but favorable associations in BRCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MYH4 RNA expression.
This table summarizes MYH4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in BLCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for MYH4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYH4 shows lower tumor expression in HNSC and KICH and higher tumor expression in BLCA, LIHC, COAD and BRCA. The BLCA box plot shows higher MYH4 RNA expression in tumor versus normal tissue (log2 FC = +0.038, t-test p = .016).
This table shows molecular features associated with MYH4 in patient tissues and cancer cell lines. In patient samples, MYH4 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, MYH4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and LARGE_INTESTINE.
